The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis.
The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis.
复制标题
阿法替尼治疗 HER2 突变非小细胞肺癌患者的疗效：荟萃分析
DOI：
10.21037/tcr.2020.04.09
复制
发表时间：
2020-05
影响因子：
0.9
通讯作者：
Xia Y
中科院分区：
文献类型：
--
作者：
Zhou N;Zhao J;Huang X;Shen H;Li W;Xu Z;Xia Y
Erb-b2受体酪氨酸激酶2 （ErbB2/HER2）突变已在约2 - 4%的非小细胞肺癌（NSCLC）患者中发现，并已被确定为致癌突变之一。Afatinib作为不可逆HER家族抑制剂的一员，已被大量文献研究，但其治疗HER2突变NSCLC的疗效尚不确定。为了阐明阿法替尼治疗HER2突变型NSCLC的临床疗效和安全性，我们整合并重新分析了现有研究的数据。我们对有关阿法替尼治疗her2突变肺癌的已发表文章进行了系统的文献检索。8项研究符合纳入和排除标准。主要观察指标为客观缓解率（ORR）和疾病控制率（DCR）。从8项研究中确定了95例HER2突变患者。合并ORR为21% (95% CI: 11-34%)，合并DCR为66% （95% CI: 57-76%）。携带a775 - g776 - YVMA突变（HER2外显子20突变最常见的亚型）的患者获得了更大的临床获益。除1例可能与阿法替尼有关的致死性急性肾损伤外，大多数不良事件为1-2级。在HER2突变型NSCLC中，阿法替尼单药治疗显示出令人沮丧的抗肿瘤活性和可耐受的毒性。根据现有数据，我们不建议在HER2突变的NSCLC中常规应用阿法替尼，除非进一步明确HER2突变的特异性基因组变异的反应异质性。
Erb-b2 receptor tyrosine kinase 2 (ErbB2/HER2) mutation has been found in approximately 2–4% of non-small cell lung cancer (NSCLC) patients and has been identified as one of carcinogenic mutations. Afatinib, a member of irreversible HER family inhibitor, has been investigated by a number of literatures, yet whose therapeutic efficiency remains uncertain in NSCLC with HER2 mutation. To elucidate the clinical efficacy and safety of afatinib in treating HER2 mutant NSCLC, we integrated and reanalyzed the data from current available studies. We conducted a systematic literature search for published articles regarding afatinib treating HER2-mutant lung cancer. Eight studies met the inclusion and exclusion criteria. The main outcomes were the objective response rate (ORR) and disease control rate (DCR). Ninety-five patients with HER2 mutations were identified from eight studies. The pooled ORR was 21% (95% CI: 11–34%) and the pooled DCR was 66% (95% CI: 57–76%). The patients harboring A775-G776ins YVMA mutation, the most common subtype of HER2 exon 20 mutation, derived greater clinical benefit. Most adverse events were grade 1–2, except a case of fatal acute renal injury, possibly related to afatinib. Afatinib monotherapy demonstrated frustrating anti-tumor activity with tolerable toxicity in HER2 mutant NSCLC. Based on current available data, we do not recommend the regular application of afatinib in NSCLC with HER2 mutations unless the response heterogeneity with specific genomic variant of HER2 mutation was further clarified.
登录
查看更多内容
影响因子：
64.8
作者：
Hyman DM;Piha-Paul SA;Won H;Rodon J;Saura C;Shapiro GI;Juric D;Quinn DI;Moreno V;Doger B;Mayer IA;Boni V;Calvo E;Loi S;Lockhart AC;Erinjeri JP;Scaltriti M;Ulaner GA;Patel J;Tang J;Beer H;Selcuklu SD;Hanrahan AJ;Bouvier N;Melcer M;Murali R;Schram AM;Smyth LM;Jhaveri K;Li BT;Drilon A;Harding JJ;Iyer G;Taylor BS;Berger MF;Cutler RE Jr;Xu F;Butturini A;Eli LD;Mann G;Farrell C;Lalani AS;Bryce RP;Arteaga CL;Meric-Bernstam F;Baselga J;Solit DB
通讯作者：
Solit DB
影响因子：
6.2
作者：
Pillai RN;Behera M;Berry LD;Rossi MR;Kris MG;Johnson BE;Bunn PA;Ramalingam SS;Khuri FR
通讯作者：
Khuri FR
影响因子：
120.7
作者：
Kris, Mark G.;Johnson, Bruce E.;Berry, Lynne D.;Kwiatkowski, David J.;Iafrate, A. John;Wistuba, Ignacio I.;Varella-Garcia, Marileila;Franklin, Wilbur A.;Aronson, Samuel L.;Su, Pei-Fang;Shyr, Yu;Camidge, D. Ross;Sequist, Lecia V.;Glisson, Bonnie S.;Khuri, Fadlo R.;Garon, Edward B.;Pao, William;Rudin, Charles;Schiller, Joan;Haura, Eric B.;Socinski, Mark;Shirai, Keisuke;Chen, Heidi;Giaccone, Giuseppe;Ladanyi, Marc;Kugler, Kelly;Minna, John D.;Bunn, Paul A.
通讯作者：
Bunn, Paul A.
影响因子：
11.2
作者：
Kosaka T;Tanizaki J;Paranal RM;Endoh H;Lydon C;Capelletti M;Repellin CE;Choi J;Ogino A;Calles A;Ercan D;Redig AJ;Bahcall M;Oxnard GR;Eck MJ;Jänne PA
通讯作者：
Jänne PA
DOI：
10.1016/j.jtho.2016.02.016
发表时间：
2016-06
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Costa DB;Jorge SE;Moran JP;Freed JA;Zerillo JA;Huberman MS;Kobayashi SS
通讯作者：
Kobayashi SS